Status:
UNKNOWN
Daily Home Spirometry for Early Detection of Pulmonary Complications in Patients With COVID19
Lead Sponsor:
Sheba Medical Center
Conditions:
COVID 19
Eligibility:
All Genders
18-85 years
Brief Summary
The aim of this preliminary study is to describe the potential decline in forced expiratory volume in 1 second (FEV1) or forced vital capacity (FVC) as measured by home spirometry in high-risk subject...
Eligibility Criteria
Inclusion
- without dyspnea and with no evidence of pneumonia, ARDS, organ failure or requiring admission to ICU.
- All patients ≥55 years age or ≥1 risk factor for disease complications (prior pulmonary, kidney or cardiovascular disease, diabetes mellitus, hypertension, bone merrow suppression, solid organ transplant, HIV with CD4\<250, heavy smoker, BMI \>30). All participants will sign a written informed consent.
Exclusion
- Patients unable to perform spirometry
- contraindications for spirometry (hemoptysis, active tuberculosis, syncope associated with forced exhalation or increased risk for spirometry)
- adhere to the follow-up protocol.
Key Trial Info
Start Date :
August 8 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2022
Estimated Enrollment :
90 Patients enrolled
Trial Details
Trial ID
NCT04438863
Start Date
August 8 2020
End Date
January 1 2022
Last Update
November 29 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Sheba Medical Center
Ramat Gan, Israel